ID   OCUT-1
AC   CVCL_6017
SY   Ocut-1; OCUT1; Osaka City University Thyroid-1
DR   BTO; BTO:0004846
DR   cancercelllines; CVCL_6017
DR   Cosmic; 1152123
DR   Cosmic; 1239960
DR   Cosmic; 1280045
DR   Cosmic; 1507372
DR   Cosmic; 1533548
DR   Cosmic; 1536125
DR   Cosmic; 1889003
DR   Cosmic; 2054107
DR   Cosmic; 2319852
DR   Cosmic; 2791081
DR   Wikidata; Q54931845
RX   PubMed=12210034;
RX   PubMed=23833040;
RX   PubMed=24357248;
RX   PubMed=30737244;
CC   Population: Japanese.
CC   Doubling time: 34 hours (PubMed=12210034).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23833040; PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Homozygous; Note=In promoter (PubMed=23833040).
CC   Omics: Transcriptome analysis by microarray.
CC   Miscellaneous: Cell line has been lost (PubMed=24357248).
CC   Derived from site: In situ; Thyroid gland; UBERON=UBERON_0002046.
ST   Source(s): PubMed=30737244
ST   Amelogenin: X
ST   CSF1PO: 12,13
ST   D13S317: 8
ST   D16S539: 10,12
ST   D18S51: 19,20
ST   D21S11: 30
ST   D3S1358: 15
ST   D5S818: 9,13
ST   D7S820: 11,13
ST   D8S1179: 15,17
ST   FGA: 21,22
ST   TH01: 6,9
ST   TPOX: 8,11
ST   vWA: 16,18
DI   NCIt; C3878; Thyroid gland anaplastic carcinoma
DI   ORDO; Orphanet_142; Anaplastic thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   74Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 20
//
RX   PubMed=12210034; DOI=10.1002/jso.10122;
RA   Ogisawa K., Onoda N., Ishikawa T., Takenaka C., Inaba M., Ogawa Y.,
RA   Chung K.H.-Y.S.;
RT   "Establishment and characterization of OCUT-1, an undifferentiated
RT   thyroid cancer cell line expressing high level of telomerase.";
RL   J. Surg. Oncol. 80:197-203(2002).
//
RX   PubMed=23833040; DOI=10.1210/jc.2013-2383;
RA   Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M.,
RA   Ibrahimpasic T., Ghossein R.A., Fagin J.A.;
RT   "Frequent somatic TERT promoter mutations in thyroid cancer: higher
RT   prevalence in advanced forms of the disease.";
RL   J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013).
//
RX   PubMed=24357248; DOI=10.1007/s00268-013-2409-7;
RA   Onoda N., Nakamura M., Aomatsu N., Noda S., Kashiwagi S., Hirakawa K.;
RT   "Establishment, characterization and comparison of seven authentic
RT   anaplastic thyroid cancer cell lines retaining clinical features of
RT   the original tumors.";
RL   World J. Surg. 38:688-695(2014).
//
RX   PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953;
RA   Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C.,
RA   Copland J.A. III, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N.,
RA   Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R.,
RA   Fagin J.A., Schweppe R.E.;
RT   "Comprehensive genetic characterization of human thyroid cancer cell
RT   lines: a validated panel for preclinical studies.";
RL   Clin. Cancer Res. 25:3141-3151(2019).
//